谷氨酰胺补充治疗对严重成人烧伤患者的疗效:系统评价与试验序贯Meta分析
该系统评价与试验序贯Meta分析纳入10项RCT共1577例严重成人烧伤患者,评估肠内或静脉谷氨酰胺补充对死亡率的影响。结果显示谷氨酰胺对总死亡率(RR 0.65,95%CI 0.33-1.28;p=0.21)、感染并发症(RR 0.83,95%CI 0.63-1.09;p=0.18)及其他次要结局均无显著影响。亚组分析中单中心与多中心RCT间存在显著亚组效应,单中心RCT中谷氨酰胺显著降低死亡率和感染并发症,但多中心RCT中无此效应;试验序贯分析表明单中心RCT的合并结果属1型错误,进一步试验将无意义。结论认为谷氨酰胺补充无论给药途径如何,似乎不能改善严重成人烧伤患者的临床结局。
要点
- 共纳入10项RCT、1577例严重成人烧伤患者,谷氨酰胺补充对总死亡率无显著影响(RR 0.65,95%CI 0.33-1.28;p=0.21)。
- 谷氨酰胺对感染并发症亦无显著影响(RR 0.83,95%CI 0.63-1.09;p=0.18)。
- 按给药途径或烧伤严重程度进行的亚组分析均未观察到显著效应。
- 单中心与多中心RCT间存在显著亚组效应:单中心RCT中谷氨酰胺显著降低死亡率和感染并发症,多中心RCT中则无。
- 试验序贯分析显示单中心RCT的合并结果属1型错误,进一步试验将无意义。
适用人群与场景
- 严重成人烧伤患者(纳入标准为评估肠内或静脉单独补充谷氨酰胺的RCT)。
研究设计与关键结果
- 研究类型:系统评价与试验序贯Meta分析,纳入10项RCT共1577例严重成人烧伤患者。
- 干预与对照:肠内或静脉单独补充谷氨酰胺 vs 对照。
- 主要终点:总死亡率无显著影响(RR 0.65,95%CI 0.33-1.28;p=0.21)。
- 次要终点:感染并发症无显著影响(RR 0.83,95%CI 0.63-1.09;p=0.18);其他次要结局亦无显著影响。
- 亚组分析:按给药途径或烧伤严重程度未见显著效应;单中心与多中心RCT间存在显著亚组效应,单中心RCT中谷氨酰胺显著降低死亡率和感染并发症,多中心RCT中无此效应。
- 试验序贯分析:单中心RCT的合并结果属1型错误,进一步试验将无意义。
证据类型、等级与局限
- 证据类型:系统评价与试验序贯Meta分析(基于RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,谷氨酰胺补充无论给药途径如何,似乎不能改善严重成人烧伤患者的临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Evidence supporting glutamine supplementation in severe adult burn patients has created a state of uncertainty due to the variability in the treatment effect reported across small and large randomized controlled trials (RCTs). We aimed to systematically review the effect of glutamine supplementation on mortality in severe adult burn patients.
DATA SOURCES: MEDLINE, Embase, CINAHL, and Cochrane Central were searched from inception to February 10, 2023.
STUDY SELECTION: RCTs evaluating the effect of enteral or IV glutamine supplementation alone in severe adult burn patients were included.
DATA EXTRACTION: Two reviewers independently extracted data on study characteristics, burn injury characteristics, description of the intervention between groups, adverse events, and clinical outcomes.
DATA SYNTHESIS: Random effects meta-analyses were performed to estimate the pooled risk ratio (RR). Trial sequential analyses (TSA) for mortality and infectious complications were performed. Ten RCTs (1,577 patients) were included. We observed no significant effect of glutamine supplementation on overall mortality (RR, 0.65, 95% CI, 0.33-1.28; p = 0.21), infectious complications (RR, 0.83; 95% CI, 0.63-1.09; p = 0.18), or other secondary outcomes. In subgroup analyses, we observed no significant effects based on administration route or burn severity. We did observe a significant subgroup effect between single and multicenter RCTs in which glutamine significantly reduced mortality and infectious complications in singe-center RCTs but not in multicenter RCTs. However, TSA showed that the pooled results of single-center RCTs were type 1 errors and further trials would be futile.
CONCLUSIONS: Glutamine supplementation, regardless of administration, does not appear to improve clinical outcomes in severely adult burned patients.
参考来源
- Ortiz-Reyes L, Lee ZY, Chin Han Lew C, et al. The Efficacy of Glutamine Supplementation in Severe Adult Burn Patients: A Systematic Review With Trial Sequential Meta-Analysis. Crit Care Med. 2023. PMID: 37114912. doi:10.1097/CCM.0000000000005887
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。